A trial of Bristol-Myers Squibb’s immune system booster Opdivo has been stopped
early after a survival benefit for patients with advanced kidney cancer was
demonstrated.
An Independent Data Monitoring
Committee put an early stop to the Phase III study after interim analysis
concluded that it met its primary endpoint, showing that the PD-1 inhibitor beat
Afinitor (everolimus) in improving overall survival.
Read more at: http://www.pharmatimes.com/Article/15-07-20/Opdivo_trial_halted_early_on_survival_benefit_in_kidney_cancer.aspx#ixzz3galrSzSV
An Independent Data Monitoring
Committee put an early stop to the Phase III study after interim analysis
concluded that it met its primary endpoint, showing that the PD-1 inhibitor beat
Afinitor (everolimus) in improving overall survival.
Opdivo (nivolumab) has already
caused quite a stir as a treatment for advanced skin cancer and metastatic
non-small cell lung cancer, but according to BMS this is the first time an
immuno-oncology agent has shown a survival advantage in advanced renal cell
carcinoma (RCC), “a patient group that currently has limited treatment
options”.
Read more at: http://www.pharmatimes.com/Article/15-07-20/Opdivo_trial_halted_early_on_survival_benefit_in_kidney_cancer.aspx#ixzz3galrSzSV
No comments:
Post a Comment